Ivivi Health Sciences commercializes the Ivivi Torino II, a portable, battery-operated non-invasive device that delivers targeted low-intensity, time-variant electromagnetic fields (tPEMF) to reduce post-operative pain and edema. Peer-reviewed preclinical and clinical data cited by the company indicate tPEMF accelerates a Ca+/CaM-dependent nitric oxide cascade, reduces IL-1β production, and promotes anti-inflammatory and tissue-repair processes. The company says Torino II produces rapid, durable pain and swelling reductions comparable to or in some cases superior to narcotics and NSAIDs, without associated narcotic or gastrointestinal side effects. Ivivi plans to accelerate commercialization through a newly formed subsidiary, Ivivi Orthopedic Health, Inc., and expand clinical development into additional musculoskeletal diseases including knee osteoarthritis. The company emphasizes the device’s safety and tolerability and cites a network of academic and clinical advisors supporting its development. Ivivi was founded in 2010 and is headquartered in San Francisco, with the orthopedic commercialization subsidiary based in Seattle.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2011